JRP
CYTK icon

Jasper Ridge Partners’s Cytokinetics CYTK Stock Holding History

Jasper Ridge Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$469K Hold
5,500
– – 0.01% 114
2026
Q1 		$363K Hold
5,500
– – 0.01% 114
2025
Q4 		$349K Buy
+5,500
New +$342K 0.01% 117

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jasper Ridge Partners's CYTK Position: Q2 2026 in Review

Jasper Ridge Partners held its Cytokinetics (CYTK) position steady in Q2 2026 at 5,500 shares worth $469K. The position accounts for 0.01% of the portfolio, ranked #114.

Jasper Ridge Partners first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Jasper Ridge Partners held 5,500 shares of Cytokinetics worth $469K as of Q2 2026.
  • Jasper Ridge Partners left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up 0.01% of Jasper Ridge Partners's portfolio in Q2 2026, its #114 holding.
  • Jasper Ridge Partners first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Jasper Ridge Partners's 13F filing for Q2 2026, filed 13 Aug 2026.